🔗 Permalink

Assignee profile:

PRISM PHARMA CO., LTD.

City:

Kanagawa

Country:

Japan

Published Applications:

Last publication date:

2018-07-05

Patent Grants:

Last grant date:

2022-06-28

Top Inventors for applications by PRISM PHARMA CO., LTD.

These are the the leading inventors for applications assigned to PRISM PHARMA CO., LTD.:

Hiroyuki Kouji 11 Kanagawa, Japan
Takenao Odagami 11 Kanagawa, Japan
Michinori Kohara 2 Tokyo, Japan
Ikuo KUSHIDA 2 Ibaraki, Japan

Yukiko SUGAYA 2 Ibaraki, Japan
Satoshi Inoue 1 Tsukuba, Japan
Takenao Odagami 1 Yokohama, Japan
Minetaka ISOMURA 1 Ibaraki, Japan

Yuji Yamamoto 1 Tsukuba, Japan
Yusaku Hori 1 Tsukuba, Japan
Mitsuo NAGAI 1 Ibaraki, Japan
Yuki KOSAKA 1 Ibaraki, Japan

Hiroyuki Kouji 1 Yokohama, Japan
Yoichi Ozawa 1 Tsukuba, Japan
Kentaro Iso 1 Tsukuba, Japan
Howard DITTRICH 1 La Jolla, CA United States

Recent patent applications by PRISM PHARMA CO., LTD.

PRISM PHARMA CO., LTD. based in Kanagawa, JP has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2018-07-05 ✅ Patent 11,369,623 granted on 2022-06-28

US20180185395A1

Human necessities

Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

#2 | 2017-09-21 ✅ Patent 10,265,331 granted on 2019-04-23

US20170266212A1

Human necessities

Prevention or treatment agent for hepatic fibrosis

#3 | 2016-11-03

US20160318957A1

Chemistry; metallurgy

CRYSTAL (1) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND

#4 | 2016-11-03

US20160318938A1

Chemistry; metallurgy

CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND

#5 | 2016-08-25

US20160244453A1

Chemistry; metallurgy

TREATMENT OF VIRAL AND INFECTIOUS DISEASES USING AN INHIBITOR OF CBP/CATENIN

#6 | 2016-07-28

US20160215007A1

Chemistry; metallurgy

METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND

#7 | 2016-06-16

US20160166578A1

Human necessities

METHOD FOR TREATING TYPE I AND TYPE II DIABETES

#8 | 2016-06-16

US20160166577A1

Human necessities

TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN

#9 | 2015-10-29 ✅ Patent 9,700,569 granted on 2017-07-11

US20150306115A1

Human necessities

Prevention or treatment agent for hepatic fibrosis

#10 | 2015-10-08

US20150284393A1

Chemistry; metallurgy

METHODS FOR TREATING EYE DISORDERS

#11 | 2015-10-08

US20150283145A1

Human necessities

TREATMENT OF HYPERPROLIFERATIVE AND PRE-CANCEROUS SKIN DISEASES USING AN INHIBITOR OF CBP/CATENIN

#12 | 2015-10-01

US20150274751A1

Chemistry; metallurgy

TREATMENT OF SCLERODERMA USING AN INHIBITOR OF CBP/CATENIN

#13 | 2015-06-25 ✅ Patent 9,174,998 granted on 2015-11-03

US20150175615A1

Chemistry; metallurgy

(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound

Also check out PRISM Pharma Co., Ltd.'s (Kanagawa, Japan) applicant profile with 2 patent applications submitted.

AssigneeID:

99341 ⎘